ReviewViruses2012
Potential vaccines and post-exposure treatments for filovirus infections.
Review in Viruses, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04186000 (Open-label Phase 2 Study to Evaluate the Immunogenicity and Safety of a Prophylactic Vaccination of Health Care Providers by Administration of a Heterologous Vaccine Regimen Against Ebola in the Democratic Republic of the Congo), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Open-label Phase 2 Study to Evaluate the Immunogenicity and Safety of a Prophylactic Vaccination of Health Care Providers by Administration of a Heterologous Vaccine Regimen Against Ebola in the Democratic Republic of the Congo
Who cites it
19 citing papers in PubMed.
- Rational design of next-generation filovirus vaccines combining glycoprotein stabilization and nanoparticle display with glycan modification.Nature communications · 2025Article
- Rational design of next-generation filovirus vaccines through glycoprotein stabilization, nanoparticle display, and glycan modification.bioRxiv : the preprint server for biology · 2025Article
- A Historical Review of Military Medical Strategies for Fighting Infectious Diseases: From Battlefields to Global Health.Biomedicines · 2022Review
- UK vaccines network: Mapping priority pathogens of epidemic potential and vaccine pipeline developments.Vaccine · 2019Article
- Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.Human vaccines & immunotherapeutics · 2019Review
- Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.Journal of virology · 2018Article
- Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice.Journal of virology · 2017Article
- Molecular mechanisms of Ebola pathogenesis.Journal of leukocyte biology · 2016Review
- Ebola virus disease and critical illness.Critical care (London, England) · 2016Review
- Post-exposure treatment of Ebola virus disease in guinea pigs using EBOTAb, an ovine antibody-based therapeutic.Scientific reports · 2016Article
- Development of Small-Molecule Antivirals for Ebola.Medicinal research reviews · 2015Review
- Three minimal sequences found in Ebola virus genomes and absent from human DNA.Bioinformatics (Oxford, England) · 2015Article
- Pathophysiology of Ebola Virus Infection: Current Challenges and Future Hopes.ACS infectious diseases · 2015Article
- Ebola and Marburg haemorrhagic fever.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2015Review
- Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment.Science (New York, N.Y.) · 2015Article
- Article
- Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb.Scientific reports · 2013Article
- Animal models for Ebola and Marburg virus infections.Frontiers in microbiology · 2013Review
- Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.Virologica Sinica · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viruses of the family Filoviridae represent significant health risks as emerging infectious diseases as well as potentially engineered biothreats. While many research efforts have been published offering possibilities toward the mitigation of filoviral infection, there remain no sanctioned therapeutic or vaccine strategies. Current progress in the development of filovirus therapeutics and vaccines is outlined herein with respect to their current level of testing, evaluation, and proximity toward human implementation, specifically with regard to human clinical trials, nonhuman primate studies, small animal studies, and in vitro development. Contemporary methods of supportive care and previous treatment approaches for human patients are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.